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Abstract
Objective
The contraceptive needs of illicit opioid users differ from non-drug users but are poorly un-
derstood. The aim of this study was to describe contraceptive use and pregnancy outcomes
in opioid-using women, and to examine their association with a range of risk factors.
Method
This retrospective cohort study used UK general practice records, Treatment Outcomes
Profile and National Drug Treatment Monitoring System data, and a nested data validation
exercise. A cohort of 376 women aged 20–61 years were in active treatment for opioid ad-
diction in October 2010 at two specialised primary care practices in North-East England.
Outcomes were age-adjusted prevalence estimates for contraceptive use and pregnancy
outcomes in users of illicit opioids. The association between lifestyle-related risk factors and
contraception was explored.
Results
Drug-using women made lower use of planned (non-condom) contraception (24% vs 50%,
p<0.001), had more frequent pregnancy terminations (0.46 vs. 0.025, p = 0.004) and higher
annual incidence of chlamydia (1.1% vs. 0.33%, p<0.001), when compared with age-
matched population data. Specifically, there was low use of oral contraceptives (4% vs.
25%, p<0.001), IUCD (1% vs. 6%, p<0.001), and sterilisation (7% vs. 6%, p = 0.053), but
higher rates of injectable contraceptives (6% vs. 3%, p = 0.003). A total of 64% of children
aged<16 years born to this group did not live with their mother. No individual risk factor
(such as sex-working) significantly explained the lower use or type of non-
condom contraception.
PLOS ONE | DOI:10.1371/journal.pone.0116231 March 4, 2015 1 / 13
a11111
OPEN ACCESS
Citation: Cornford CS, Close HJ, Bray R, Beere D,
Mason JM (2015) Contraceptive Use and Pregnancy
Outcomes among Opioid Drug-Using Women: A
Retrospective Cohort Study. PLoS ONE 10(3):
e0116231. doi:10.1371/journal.pone.0116231
Academic Editor: Irene Petersen, UCL, UNITED
KINGDOM
Received: April 8, 2014
Accepted: December 5, 2014
Published: March 4, 2015
Copyright: © 2015 Cornford et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All data are unsuitable
for deposit as small numbers may threaten patient
anonymity. The relatively unique characteristics of
patients in this cohort may render them recognisable.
Data are available on request from Dr Helen Close
( h.j.close@durham.ac.uk).
Funding: The authors report no current funding
sources for this study.
Competing Interests: The authors have declared
that no competing interests exist.
Conclusions
This is the first study to describe planned contraceptive use among drug-users, as well as
the association with a range of risk factors and pregnancy outcomes. The low uptake of
planned contraception, set against high rates of terminations and sexually transmitted dis-
ease demonstrates the urgent clinical need to improve contraceptive services, informed by
qualitative work to explore the values and beliefs influencing low contraceptive uptake.
Introduction
In England, women addicted to heroin or crack cocaine account for 4.05/1000 of the popula-
tion (aged 15–64) [1]. Heroin use has devastating effects for both men and women, but women
are subject to a whole range of additional challenges relating to sexual relations with men, con-
traception, pregnancy and child bearing [2–8]. Preconception and prenatal drug and alcohol
use may directly cause poor maternal outcomes as well as adverse effects on the developing foe-
tus, with life-long consequences [2]. Multiple sexual partners, sex work, chaotic life styles, and
a high prevalence of sexually transmitted disease impact both on the type of contraception
used and the type that would be most appropriate [4]. Women’s attitudes towards contracep-
tion may be affected by several factors, including amenorrhoea, fatalistic ideas and problematic
relationships with men [5]. However, little is known about the choices drug-using women
make about their contraception, or about subsequent pregnancy outcomes. Much evidence is
drawn from undifferentiated populations in which drug use is commonplace.
Within the UK general population, in 2008/09, around 75% of women under 50 were using
at least one method of contraception with the contraceptive pill and the male condom cited as
most popular methods of contraception (25% each), followed by partner sterilisation (11%) and
self-sterilisation (6%). Around 25% were not using contraception, of whom just over a half
(13%) reported not being engaged in a heterosexual relationship [9]. These trends are reflected
worldwide, apart from on the African continent in which contraception use is around 30% [10].
There is some knowledge about patterns of contraception use in drug using groups and in
groups sharing similar features [11]. In a group of women in treatment for drug addiction in
America, 76% of pregnancies were unplanned and 62% of the women having sex in the previ-
ous month had not used any contraceptive [12]. The use of non-condom contraception is sur-
prisingly low in sex-workers: only 48% of parlour-based workers and 11% of street workers
reported using contraception in addition to condoms [13]. A survey of contraceptive use in
hepatitis C positive women in Australia found that only 34% used any form of contraception
compared to 67% in a national survey [14]. Of those with hepatitis C and using contraception,
50% used barrier methods compared to 21% in the national survey. Incarcerated women have
poor use of any contraception, and high rates of unplanned pregnancies, multiple partners and
Sexually Transmitted Infections (STIs) [15]. A survey of intravenous drug users in New York
showed 26% reported any contraceptive use compared to 48% use in women based on a na-
tional survey [16].
Although appropriate condom use is proven to reduce the risk of sexually transmitted infec-
tions, non-condom contraception may be more acceptable for women who have chaotic life
styles or are intoxicated at the time of intercourse [17]. However, the uptake of non-condom
contraception in this population remains unknown. Research into contraceptive use amongst
opioid drug users is largely dated, does not make a clear distinction between condom and non-
condom use, and assumes that drug users are a homogenous group in terms of their lifestyles,
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drug choices, behaviours and medical profiles. There is limited evidence supporting the need
for a more personally tailored and heterogeneous approach taking into account use of illicit
drugs, medication and the personal context of the drug user. Nevertheless, there is a particular
need for effective contraception in this group. The effects of drug use in pregnancy are difficult
to determine because of a wide range of confounding variables including poly-drug use. Co-
caine and heroin use in pregnancy are associated with intra-uterine growth retardation; alcohol
use, which is associated with illicit drug use, additionally has well-known teratogenic effects [2]
[6]. Mothers using opiates are particularly concerned about neonatal withdrawal syndrome [7].
Successful pregnancies may, in some cases, lead to a further range of potential problems includ-
ing pressures on other family members to take on the care of children, legal proceedings and
the ‘bereavement’ of children being taken into care [3] [8] although the relationship between
child protection issues and contraception remains complex and poorly described. For example,
the permanent residence of children born to this population (a proxy for child protection pro-
ceedings) is poorly understood within both UK and non-UK contexts.
As well as the need for effective contraception, effective protection against STIs is often re-
quired. Intravenous drug use is associated with hepatitis C and HIV, and high levels of other
sexually transferrable infections have been documented in incarcerated women [4] [11]. Multi-
ple sexual partners and a high prevalence of sexually transmitted diseases were found in a
study of drug treatment services in America over 20 years ago [12]. Drug use is common in sex
workers, particularly in street-based workers in whom it is almost universal [18]. Within this
group, use of crack cocaine makes condom use less likely [17].
A range of problems associated with contraception have been demonstrated in drug-using,
or related, groups. Poor knowledge about contraception includes exaggerated worries about
the dangers of contraceptive use and fatalistic views about the occurrence of pregnancy [17].
Amenorrhoea is induced by heroin (and to a lesser extent by methadone) through the hypotha-
lamic-pituitary axis and is aggravated by loss of weight [5]. This may also impact on attitudes
of women who may then believe their fertility is low [19]. Troubled childhood and adolescence,
coercive relationships with men including sex in exchange for drugs and male dominated cul-
tures are some of the difficulties faced by women using crack cocaine [8]. The high levels of
mental health disorders in opiate users [20] may also impact on contraceptive use. Other diffi-
culties include the need to trust despite experiencing fragile relationships, and the common oc-
currence of past and present violence, rape and sexual abuse [11]. Women in this group
frequently experience grief from previous losses, poor self-esteem, feelings of shame, poor self-
efficacy, poor social and negotiating skills, chaotic life styles, difficulty in keeping appointments
and a general mistrust of health professionals who either may stigmatise drug users or misun-
derstand them [8][11][12].
Thus this is the first study to describe planned contraceptive use among a British cohort of
opioid drug-users and its potential associations with a range of behavioural, relationship, phys-
ical and psychiatric risk factors. Additionally, this study presents a unique opportunity to de-
scribe pregnancy outcomes (including the residential destination of the child). This will inform
future research into the complex, multi-factorial relationships between family planning and
pregnancy outcomes.
Method
The primary aims of the study were descriptive: to provide crude, and age adjusted prevalence
estimates for contraceptive use and pregnancy outcomes in women currently receiving opioid-
substitution treatment (OST) for addiction to illicit opioids (injecting and non-injecting) in a
specialist community care setting. The secondary aim was to explore the association between
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current heroin use and use of planned (non-condom) contraceptives, adjusting for a range of
behavioural, social, physical and psychiatric risk factors.
Sample and setting
A convenience sampling frame was adopted in which contraceptive and pregnancy histories
were retrieved for all 376 female patients receiving OST (methadone or buprenorphine) and who
were registered for general medical services (GMS) at two Medical Practices in Middlesbrough
and Stockton-on-Tees, which serve a region of relative deprivation in the north of England. Data
extraction occurred in June 2011. The practices both provide specialist treatment services for opi-
oid addiction to patients from the surrounding area. These practices had a total of 1,332 patients
at the time of the survey who either had drug addiction problems requiring medical treatment or
were children of such patients. The practices are otherwise ‘standard’ general practices, offering
the usual range of primary care services. The specialist Middlesbrough practice provided OST for
all patients receiving treatment for opiates in the surrounding area. These patients could be regis-
tered for general medical services (GMS) at the specialist practice or at other practices in the
Middlesbrough area: this study only includes patients registered at the specialist practice. Previ-
ous research has demonstrated no significant differences in terms of age, gender or ethnicity ac-
cording to where OST patients receive GMS [21]. The percentage of female patients receiving
OST was 30% and mean age was 33: both similar to national figures [1].
Measures
The Treatment Outcomes Profile (TOP) measure is a validated self-report tool, routinely com-
pleted in UK drug treatment settings, assessing change and progress in key areas of the lives of
people in treatment for drug addiction. TOP includes: frequency, mode, and type of illicit drug
use; social functioning (housing, employment, and education status); subjective health and psy-
chological status; criminal activity; and, activities and behaviours that have occurred in the pre-
ceding 4 weeks [22]. A TOP measure was completed for each patient every 3 months, with the
most recent being used in the analysis. Use of illicit drugs within the preceding 4 weeks was
used to define ‘current’ drug use.
Data from the National Drug Treatment Monitoring System form [23] was also available
for all patients in treatment. This is completed by all drug treatment agencies in England in
order to monitor performance against local and national targets; these included information
such as ethnicity, hepatitis B vaccination status, hepatitis C testing status, illicit drugs used, and
sex-worker status. Data were extracted from the practice records using a search, including: con-
traceptive use, pregnancies, terminations, miscarriages, still and live births, family composition,
sexually transmitted diseases, cervical testing and sex work.
Contraceptive use was defined as the method recorded in GP prescription records, and
non-barrier contraception was defined as any record of any non-barrier method. Contracep-
tion was classified as ‘current’ or ‘past’ according to whether use would still have been active.
For example if a six month prescription for the combined contraceptive pill was recorded less
than six months before the time of the note search, this would be noted as ‘current’; if issued
more than six months ago it would be recorded as ‘previous’.
Validation
Assessing lifestyle and behavioural factors such as the level of abuse experienced by female opi-
ate users is problematic since it depends upon self-report and the context in which information
is sought. These factors are of particular interest because of their potential role in contraceptive
choices. However, recording within the TOP data set was found to be too incomplete to provide
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a reliable assessment of such factors. Thus, a validation exercise was conducted at one of the two
practices (including 176 patients), assessing previous involvement in sex work, sexual abuse, and
domestic violence. A total of 10 keyworkers (health care worker responsible for the drug addic-
tion treatment of individual patients) were interviewed and asked a series of questions with bina-
ry (yes/no) answers about each individual patient within the current cohort registered at their
practice. Two meetings were arranged with the keyworkers in a group setting. They were asked
to provide the information for each patient in turn. Each keyworker had worked with an indi-
vidual patient for a length of time varying from weeks to many years. Some patients had received
care frommore than one keyworker at different periods, so the knowledge gained was a collec-
tive response to the questions. Three of the keyworkers were not at one or both of the meetings,
and so they were asked on an individual basis to provide information for their patients.
Analysis
A search was made of the GP records of all eligible female patients over the age of 18 currently
in treatment for opiate addiction. Data capture was piloted by reviewing the notes of 10 eligible
patients to identify data recording issues. Subsequently, data from sources were combined and
anonymised before analysis; no individual patient characteristics were identifiable within the
analyses. Analysis was conducted using SPSS (version 21). When comparing estimated propor-
tions with population values, 2-sided single proportion tests were conducted against the null
population value and exact confidence intervals (CIs) were estimated. When comparing cohort
event rates with population values, indirect standardisation was employed, where the event
rate in an age-matched population cohort is estimated and the subsequent standardised event
ratio (observed/expected) is evaluated as the test statistic: = (O-E)2/E~X2[1]. Simple univariable
modelling included the full range of potential explanatory variables. Stepwise addition iterating
to the best model did not prove necessary. All estimates of test probabilities are reported for
the purpose of hypothesis generation with a 5% threshold for significance and thus without
post-hoc correction. The prospective study power calculation estimated that approximately
30% of 300 adult female patients would be current users of contraception, providing a crude
prevalence estimate with precision: 95%CI = 25% to 35%.
Ethics
This study was approved (by Chair’s action) by South Tees NHS Research Ethics committee.
Individual consent was not required, and patient data were anonymised and de-identified prior
to analysis.
Results
Demographic characteristics
Data were available for 374 female patients who were receiving treatment for illicit opioid ad-
diction; the mean age was 33 years (range 20–61 years) and 353 (94%) were recorded as white
British. All patients had previously used heroin. At initial entry into treatment, the cohort of
women had been recorded as using (non-exclusively) heroin in 337 (90%) (smoked by 168
(45%), injected by 150 (40%)), crack cocaine in 101 (27%), methadone in 30 (8%), benzodiaza-
pines in 15 (4%) and cannabis in 15 (4%); other drugs were used less frequently. The average
age of beginning drug use was 21 years (range 12 to 40). Hepatitis C testing had been con-
ducted for 269 (72%) of patients and found to be present in 82 (22%) of patients. Workforce
participation was limited with 19 (5%) of the sample in regular employment, 247 (66%) unem-
ployed, long term sick or disabled, and 108 (29%) undisclosed.
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Rates of completion of cervical smear testing were high in this group, with a record of 307
(82%) uptake within the previous three years, comparing favourably to the 79% uptake nation-
ally for women aged 25–64 [24]. Chlamydia had been diagnosed in 33 (8.9%) of subjects tested;
based on the previous three years the annual incidence was 1.1% (95% CI: 0.5% to 1.9%). Na-
tionally, the population annual incidence of chlamydia is 0.33% [25], one third of the rate in
this cohort (1.1% vs 0.33%, p<0.001). Numbers were too small to reliably interpret other dis-
ease rates against population figures.
Contraceptive use
Data were available for 376 female participants receiving OST. Current overall contraceptive
use was low at 113 (30%) when compared to a national age-standardised figure of 75%, al-
though this figure includes recorded condom use (Table 1). However, the use of non-condom
Table 1. Current and previous contraception use.
Age Category
20–29 30–39 40–49 50+ Total
N = 137 N = 189 N = 41 N = 7 N = 374
Current Contraceptive Use 39 29% 58 31% 12 29% 1 14% 110 29%
Condoms (male) 12 9% 14 7% 0 0% 0 0% 26 7%
Condoms (female) 0 0% 0 0% 0 0% 0 0% 0 0%
Non-condom contraception 31 23% 47 25% 11 27% 1 14% 90 24%
Diaphragm/cap 0 0% 0 0% 0 0% 0 0% 0 0%
Combined pill/patch/vaginal ring 8 6% 6 3% 1 2% 0 0% 15 4%
POP pill 2 2% 5 3% 2 5% 0 0% 9 2%
Injectable 12 9% 7 4% 2 5% 0 0% 21 6%
Implant 7 5% 8 4% 0 0% 0 0% 15 4%
IUCD 0 0% 2 1% 0 0% 0 0% 2 1%
IUS 0 0% 3 2% 0 0% 0 0% 3 1%
Sterilisation 3 2% 15 8% 7 17% 1 14% 26 7%
Vasectomy (partner) 1 1% 0 0% 1 2% 0 0% 2 1%
Other 1 1% 2 1% 0 0% 0 0% 3 1%
Previous Contraception Use 100 73% 145 77% 22 54% 1 14% 268 72%
Condoms (male) 50 37% 70 37% 6 15% 0 0% 126 34%
Condoms (female) 2 2% 2 1% 0 0% 0 0% 4 1%
Non-condom contraception 86 63% 129 68% 23 56% 1 14% 239 64%
Diaphragm/cap 0 0% 0 0% 0 0% 0 0% 0 0%
Combined pill/patch/vaginal ring 46 34% 77 41% 14 34% 0 0% 137 36%
POP pill 9 7% 17 9% 4 10% 0 0% 30 8%
Injectable 51 37% 81 43% 10 24% 0 0% 142 38%
Implant 12 9% 14 7% 0 0% 0 0% 26 7%
IUCD 4 3% 6 3% 4 10% 1 14% 15 4%
IUS 1 1% 4 2% 0 0% 0 0% 5 1%
Other 1 1% 1 1% 0 0% 0 0% 2 1%
Emergency contraception 23 17% 39 21% 1 2% 0 0% 63 17%
Number of occasions1 2.2 2.2 1.0 0.0 2.2
1Mean number of occurrences within each age category
doi:10.1371/journal.pone.0116231.t001
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contraception was similarly low (90 (24%) compared to 50% in the population, p<0.001).
More specifically, there was low use of oral contraceptives (15 (4%) compared to 25%,
p<0.001), IUCD (4 (1%) compared to 6%, p<0.001), similar rates of sterilisation (26 (7%)
compared to 6%, p<0.053) but higher rates of injectable contraceptives (23 (6%) compared to
3%, p = 0.003). (All comparisons based on age-adjusted national data [26]).
Pregnancies and family composition
Most subjects (323, 86%) had become pregnant at least once, with an average of 3.31 pregnan-
cies and 2.43 live births in those becoming pregnant (Table 2). Thus live births were not dis-
similar to the population norm. Using population data from England and Wales in 2010 for
mothers going to term, the average number of children expected for an age-matched cohort
was 1.97 [27], providing a Standardised Birth Ratio of 1.24, p = 0.74. However, the termination
rate was 0.46 per mother within the total cohort, far exceeding an age-matched population co-
hort of 0.025 per mother (p = 0.004).
An analysis of family composition by age shows unsurprisingly that family size grows with
age but that the majority of children under the age of 16 do not live with their maternal mother
(Table 3). Within the cohort, of 556 children aged under 16, 203 (36%) lived with their mother,
217 (39%) lived instead with their father or other family member and 113 (20%) had been
adopted or were in foster care.
Historical level of abuse
General practice note review reported previous involvement in sex work (44, 12%), sexual
abuse (61, 16%) and domestic violence (113, 30%). A validation enquiry amongst keyworkers
of client history resulted in far higher estimates (Table 4).
Table 2. History of Pregnancy.
Age Category
20–29 30–39 40–49 50+ Total
N = 137 N = 189 N = 41 N = 7 N = 374
Pregnancy 110 80% 167 88% 39 95% 6 86% 322 86%
Number of pregnanciesa 2 2 3 2 3 3 4 5 3 3
Live birthsb 91 82% 159 95% 39 100% 5 83% 294 91%
Number of live births a 1 2 2 2 2 2 3 4 2 2
Terminations b 33 30% 62 37% 15 39% 2 33% 111 35%
Number of terminations a 0 0 0 1 0 1 0 1 0 1
Ectopic pregnancies b 3 3% 3 2% 1 3% 0 0% 8 3%
Number of ectopic pregnancies a 0 0 0 1 0 0 - - 0 0
Miscarriages b 26 25% 53 32% 10 26% 4 67% 92 29%
Number of miscarriages a 0 0 0 1 0 1 1 1 0 1
Still births b 2 2% 3 2% 2 5% 0 0% 7 2%
Problems becoming pregnant 7 7% 16 10% 3 7% 1 14% 27 10%
Referral for secondary care investigation c 4 31% 10 63% 2 67% 1 100% 17 53%
Referral for reversal of Sterilisation c 1 8% 1 5% 0 0 0 0% 2 6%
a Median number (interquartile range) of events in those with at least one event
b Proportion of mothers experiencing an event who have become pregnant at least once
c Proportion of mothers referred because of problems becoming pregnant
doi:10.1371/journal.pone.0116231.t002
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Associations with planned contraceptive use
The influence of a range of patient risk factors upon planned contraceptive use was explored
(Table 5). Only history of sexual abuse was statistically significantly associated with greater
planned contraception (p = 0.03). A similar but non-statistically significant positive trend is ap-
parent for recent sexual abuse and domestic violence, while there was no statistically significant
association between lower planned contraceptive use with current opiate use (for any use or
heavy use) and sex-work.
The range of patient risk factors was further explored within sub-groups of different types
of non-condom contraception (Table 5). Similar patterns are observed although smaller num-
bers affect statistical significance. The use of IUCDs was greater with heavy cannabis use
(p = 0.03) and combined pill use was more common in alcohol users although confidence in-
tervals were wide (95% CI 1.5 to 427.4, and 1.09 to 10.7 respectively).
Discussion
Summary
This is the first cohort study to describe and evaluate the use of non-condom contraception in
illicit drug-using women in the UK. When compared to the general population, non-condom
contraceptive use was low in this group overall, with low use of oral contraceptives, IUCD, sim-
ilar rates of sterilisation, but high rates of injectable contraceptives. Within group and sub-
group analysis of age, alcohol use, current illicit opiate use, other illicit drug use, or reported
health status did not explain these patterns of contraceptive use, although it is possible that the
Table 3. Family composition according to mean (median/Interquartile range) number of children per age band.
Age Category (Mean/median/IQR)
20–29 30–39 40–49 50+ Total
N = 92 N = 159 N = 39 N = 5 N = 295
x x˜ IQR x x˜ IQR x x˜ IQR x x˜ IQR x x˜ IQR
Progeny aged 16+ 0.02 0 0–0 0.38 0 0–1 2.03 2 1–3 2.80 2 1–4 0.52 0 0–1
Children (aged <16) living with mother 0.66 0 0–1 0.74 0 0–1 0.51 0 0–1 0.20 0 0–0 0.68 0 0–1
Children not living with mother but living with father 0.13 0 0–0 0.13 0 0–0 0.00 0 0–1 0.00 0 0–0 0.11 0 0–1
Children not living with mother but living with other family member 0.75 0 0–1 0.68 0 0–1 0.05 0 0–0 0.00 0 0–0 0.61 0 0–0
Children in foster care 0.22 0 0–0 0.36 0 0–0 0.18 0 0–0 0.00 0 0–0 0.28 0 0–0
Children adopted 0.10 0 0–0 0.12 0 0–0 0.03 0 0–0 0.00 0 0–0 0.10 0 0–0
Children under 16 not included in above 0.03 0 0–0 0.13 0 0–0 0.03 0 0–0 0.20 0 0–0 0.09 0 0–0
doi:10.1371/journal.pone.0116231.t003
Table 4. Rates of abuse experienced in the past year and ever.
Sex work Sex abuse Domestic violence
Notes Keyworker1 Notes Keyworker1 Notes Keyworker1
Ever 44 (11.7%) 52 (29.5%) 61 (16.3%) 53 (30.1%) 113 (30.1%) 72 (40.8%)
Last year 5 (1.3%) 23 (13.1%) 7 (1.9%) 14 (8.0%) 17 (4.4%) 36 (20.2%)
1 Taken from validation exercise at practice A (n = 176 patients)
doi:10.1371/journal.pone.0116231.t004
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Table 5. Determinants of planned contraceptive use by type: univariable (simple) regression model ﬁndings*.
Non-condom
contraceptive use
(ALL)
Pill IUCD Injectables Sterilisation
N OR 95%CI p N OR 95%CI p N OR 95%CI P N OR 95%CI p N OR 95%CI p
Age 90 1.01 (0.97 to
1.04)
0.77 15 0.90 (0.81 to
1.00)
0.77 2 1.03 (0.84 to
1.25)
0.79 21 0.93 (0.86 to
1.02)
0.11 26 1.12 (1.06 to
1.18)
0.001
Alcohol Use1 78 1.09 (0.64 to
1.87)
0.75 13 3.41 (1.09 to
10.7)
0.04 2 2.03 (0.13 to
32.7)
0.62 21 1.26 (0.51 to
3.14)
0.62 23 0.88 (0.35 to
2.19)
0.78
Heavy Alcohol
Use1,2
78 0.75 (0.27 to
2.06)
0.58 13 2.21 (0.46 to
10.6)
0.32 2 - 21 1.25 (0.27 to
5.67)
0.77 23 -
Opiate Use1 81 0.61 (0.35 to
1.07)
0.084 14 0.38 (0.08 to
1.77)
0.22 2 1.57 (0.11 to
28.2)
0.69 21 0.94 (0.36 to
2.41)
0.89 25 0.41 (0.15 to
1.13)
0.08
Heavy Opiate
Use2
78 0.57 (0.26 to
1.28)
0.17 14 0.98 (0.21 to
4.50)
0.98 2 5.95 (0.37 to
96.9)
0.21 20 0.60 (0.14 to
2.66)
0.50 25 0.49 (0.11 to
2.14)
0.34
Crack cocaine
use1
82 0.98 (0.43 to
2.27)
0.97 14 0.79 (0.10 to
6.3)
0.83 2 - 21 0.92 (0.20 to
4.12)
0.91 25 1.28 (0.36 to
4.5)
0.71
Heavy Crack
cocaine use2
79 0.70 (0.15 to
3.32)
0.66 12 - 2 - 21 1.57 (0.19 to
12.8)
0.68 24 -
Cannabis use1 82 1.08 (0.50 to
2.31)
0.85 14 1.29 (0.28 to
5.96)
0.75 2 7.8 (0.48 to
127)
0.15 21 0.79 (0.18 to
3.54)
0.76 25 1.04 (0.30 to
3.66)
0.95
Heavy Cannabis
use2
82 1.29 (0.39 to
4.24)
0.67 14 - 2 25.3 (1.5 to
427.4)
0.03 21 2.73 (0.57 to
13.07)
0.21 25 -
Intravenous drug
use1
82 0.47 (0.19 to
1.14)
0.096 14 1.14 (0.25 to
5.29)
0.86 2 - 21 - 25 0.57 (0.13 to
2.52)
0.46
Sex worker3,4 40 0.47 (0.13 to
1.66)
0.24 8 - 2 - 5 - 17 0.39 (0.05 to
3.06)
0.37
Sex worker1, 4 40 0.78 (0.35 to
1.75)
0.55 8 - 2 - 5 0.59 (0.06 to
5.41)
0.64 16 0.78 (0.24 to
2.54)
0.68
Sexual abuse3, 4 41 1.94 (0.61 to
6.17)
0.26 8 1.7 (0.19 to
14.9)
0.63 0 - 5 - 17 1.63 (0.33 to
7.99)
0.55
Sexual abuse1, 4 41 2.24 (1.08 to
4.63)
0.030 8 2.43 (0.59 to
10.1)
0.22 0 - 5 0.57 (0.06 to
5.24)
0.62 17 1.72 (0.62 to
4.79)
0.30
Domestic
violence3, 4
40 1.72 (0.76 to
3.92)
0.20 8 4.32 (1.02 to
18.2)
0.05 0 - 5 - 17 1.75 (0.57 to
5.35)
0.33
Domestic
violence1, 4
40 1.63 (0.80 to
3.31)
0.18 8 2.53 (0.58 to
10.9)
0.22 0 - 5 0.97 (0.16 to
5.94)
0.97 17 2.25 (0.81 to
6.22)
0.12
Physical Health5 82 0.99 (0.93 to
1.05)
0.72 14 1.06 (0.93 to
1.21)
0.41 2 1.04 (0.74 to
1.46)
0.81 21 0.96 (0.87 to
1.07)
0.47 25 1.03 (0.93 to
1.13)
0.62
Psychiatric
Health5
82 0.97 (0.92 to
1.03)
0.32 14 0.99 (0.88 to
1.12)
0.91 2 1.02 (0.74 to
1.40)
0.92 21 0.98 (0.89 to
1.08)
0.69 25 0.97 (0.88 to
1.06)
0.48
Global Health5 82 1.00 (0.94 to
1.05)
0.89 14 1.11 (0.97 to
1.3)
0.11 2 0.99 (0.73 to
1.35)
0.95 21 0.96 (0.87 to
1.05)
0.34 25 0.99 (0.91 to
1.09)
0.91
1 Ever
2 More than 1 day in 2
3 In the last year
4 Keyworker assessed (N = 176 patients)
5 Assessed using TOPS data
*Model constant not shown: Cocaine, Amphetamine and other drug use not reported because of small numbers of users
- Numbers too small to analyse
doi:10.1371/journal.pone.0116231.t005
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current cohort is underpowered to find modest but important influences. Rates of chlamydia
infection were high, as were reported levels of domestic violence, past sexual abuse and sex
work. Our findings suggest a significant under-recording of domestic violence, sexual abuse,
and sex worker status. Findings also showed high levels of ectopic pregnancies, high rates of
terminations, and two-thirds of children under 16 unable to live with their mothers. Thus,
there is an urgent need to improve contraceptive services for this vulnerable group. Given the
lack of observable risk factors or evidence for observed behaviours qualitative research may be
appropriate to help understand contraceptive uptake and how contraceptive services might be
improved in this group. The higher rates of injectable contraceptives in this group suggests a
possible route for further enquiry, as does the high rate of cervical smears suggesting unexpect-
edly high levels of engagement: such clinical encounters may offer a particular opportunity for
contraceptive service development. It is possible that the high level of one-to-one long-term
support offered at the study treatment facilities gave women the opportunity to build a level of
trust and positive engagement with service providers that could be built upon for other health-
related interventions. Improving contraceptive uptake would benefit patients and have broader
societal benefits.
Strengths and limitations
Secondary use was made of medical records not designed for research purposes within retro-
spective analysis. The most obvious knowledge gap concerns the use of condoms. Practice re-
cord recording of non-condom contraceptive use within the British GP setting is reliable since
provision is by prescription or would be recorded if provided by community contraceptive clin-
ics. Recording of condom-based contraception is less reliable and thus the low current overall
contraceptive use of 30% (compared to national figures of 77%) may be underestimated. Re-
cording of sexual abuse, domestic violence and sex working status is likely to be variable and
we have modelled formal and informal records to help explore these important factors. The
Treatment Outcomes Profile (TOP) [22] measure was used as a proxy for mental ill-health and
as such it has some important limitations. It measures psychological health on a 20 point scale
and thus does not systematically capture psychiatric morbidity which may have been missed
within the current study design. Similarly, data from the National Drug Treatment Monitoring
System [23] was collected for monitoring purposes rather than primary research and thus the
information collected was limited compared to the richer data provided during key worker in-
terviews. For example, assessing the level of abuse experienced by female opiate users depends
upon self-report and the context in which information is sought: recording within the TOP
data set and GP note recording was too incomplete for research use. Thus, this is the first study
to provide a validation of practice records for domestic violence, sexual abuse (recent and his-
torical), and sex worker status via interviews with keyworkers. Although this type of reporting
may be subject to recall bias, the level of dissonance between the records and keyworker knowl-
edge suggests limitations in GP recording that warrant further investigation. It is possible that
interviews with drug-using women themselves may have revealed further levels of information
not available in routine datasets: we plan to conduct interviews in future research. Nonetheless
the relatively large cohort of opioid users permits factors affecting contraceptive use to be
meaningfully explored.
Failure to find any factors significantly explaining differences in planned contraceptive use
was surprising. It would be expected that patients with more ‘chaotic’ lifestyles, such as heavy
current alcohol use, current use of illicit opiates or domestic violence, might be less able to take
advantage of planned contraception. Presumably latent group differences between opioid using
women and non-opioid using women provide the explanation for this finding, but we are
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unable in the current study to account for what those differences might be. A hypothesis gener-
ating approach permits multiple testing to explore associations and relationships. However
findings require replicating in further research to differentiate associations and artefact find-
ings. Furthermore we accept that all epidemiological enquiry is vulnerable to confounding by
omitted variables (unmeasured influences).
Comparison with existing literature
Previous studies in groups including women treated for opioid addiction, such as sex workers,
incarcerated women and women treated for hepatitis C infection, have previously suggested a
low level of non-condom contraception although the true extent of this was unknown [13][14]
[15]. This is the first study to our knowledge to describe and evaluate the low levels of non-
condom contraceptive use in women in treatment for opioid addiction in the UK, a country
where such contraception is widely and freely available, and whose uptake is not inhibited by
negative social norms. This study showed a higher than usual current use of injectable con-
traceptive use. A previous survey of postnatal contraception in opioid using women suggested
that this group failed to continue with injectable contraception and that this might be an inap-
propriate contraceptive [28]. However, there may be differences between opioid-using women
in general and postnatal opioid-using women, warranting further exploration.
High rates of sexually transmitted infections have been documented in related groups, such
as incarcerated women and drug treatment services in America, thus a high rate of chlamydia
infections was not unexpected. Similarly, high rates of unplanned pregnancies were reported
over 20 years ago, but this is the first study to our knowledge to show high rates of pregnancies
specifically in the drug using population. Accurate population data are not available for preg-
nancy related outcomes to permit further comparison although rates of ectopic pregnancies ap-
pear high compared with prevalence estimates of around 1% based on acute hospital
admission data [29]. Despite perceptions about lack of engagement with formal services in this
group, there was a high cervical smear rate, mirroring that for women serving long-term prison
sentences [30]. This suggests that despite challenging, chaotic circumstances, women can en-
gage with personal and sexual health services, offering a possibility for future
service development.
This study is the first known study to describe the prevalence of children living apart from
their mothers in this population. Residence is an important but imperfect proxy for child pro-
tection proceedings and it is important to highlight that the study was not designed to examine
the complex and multi-factorial association between contraceptive use and parenting break-
down or child protection issues. Developing an understanding of place of residence simply pro-
vides context within which to inform future research into the development of appropriate
patient-centred services for this population.
Implications for Practice
There is an urgent clinical need to improve contraceptive services amongst drug users, with the
aim of reducing termination rates, ‘unseen’ consequences of a failure to plan such as ectopic
pregnancies, and the maternal and foetal development disorders associated with drugs and al-
cohol during conception and pregnancy. In this study, the lack of evidence for within-group as-
sociations for contraceptive use demonstrates that factors such as current drug or alcohol use,
perceived health status, sexual abuse or domestic violence should not be a barrier to uptake of
such services within the group of opiate using women. The high uptake of cervical smear test-
ing also demonstrates that it is possible to deliver high quality medical services within this
group and presents a possible opportunity in clinical practice. The high incidence of chlamydia
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infection demonstrates the need for sexually transmitted disease services for this group. Further
research is needed to explore the factors that influence contraceptive use in opiate using
women, with the aim of developing more appropriate services to reduce the burden of un-
planned pregnancies and STDs.
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